The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In the Archives

Joseph H. Ogura, Arti Hurria, and the impact of the National Cancer Act

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Upcoming

book-cover

Book Event: From Shadows to Life: A Biography of the Cancer Survivorship Movement

Join NCCS CEO Shelley Fuld Nasso, MPP, and author Judith L. Pearson for a conversation about her upcoming book.

Tuesday, March 9, 7 P.M. EST | Register for free

Quote of the week

The evacuation experience of the Japanese Americans is a harsh reminder of the frailties of the constitutional guarantees. If civil liberties can be taken away from one group, we hope that similar tragedies will never occur or be repeated again.

Joseph H. Ogura

Letter Regarding Internment of Japanese Americans Addressed to US Senator John Danforth, from Joseph H. Ogura, M.D.
By Siteman Cancer Center | Feb. 25, 2021

Japanese-American Scientists

Ogura

A collection of posts celebrating the impact on oncology by Black, Indigenous, and People of Color oncologists, researchers, and advocates will continue to be available under the tag “BIPOC Impact.”

Health Disparities

Recent contributions

City of hope Jewish-Consumptive-Relief-Association

Primary Sources

This column in The Cancer Letter features the latest posts to the Cancer History Project by our growing list of contributors.

The Cancer History Project is a free, web-based, collaborative resource intended to mark the 50th anniversary of the National Cancer Act and designed to continue in perpetuity. The objective is to assemble a robust collection of historical documents and make them freely available.

Access to the Cancer History Project is open to the public at CancerHistoryProject.com. You can also follow us on Twitter at @CancerHistProj.

Is your institution a contributor to the Cancer History Project? Would you like us to tell you about the project and how you can get involved?

Eligible institutions include cancer centers, advocacy groups, professional societies, pharmaceutical companies, and key organizations in oncology.

To apply to become a contributor, please contact admin@cancerhistoryproject.com.

Table of Contents

YOU MAY BE INTERESTED IN

Podcast

“There is no safe harbor:” FY26 funding bill collapses after ICE shooting of Alex Pretti

In last week’s issue of The Cancer Letter, Jacquelyn Cobb, associate editor, wrote a story about the then-promising legislative package that was passed by the U.S. House of Representatives Jan. 22. At the time, the package was expected to pass in the Senate, provide funding for the federal government through fiscal year 2026, and prevent a government shutdown that looms Jan. 30. 
Clinical

Premarin’s 84-year hold on the market ends as FDA approves a generic version
Trade secret protections helped the hormone drug resist generic entry and outlast safety controversies—including link to cancer

A story is told that after first obtaining approval for marketing Premarin in 1942, Wyeth Laboratories didn’t lock up the secret recipe for making the hormonal drug in a company safe, to be guarded by patent lawyers.
By Claire Marie Porter
Capitol Hill

Spending bill passed by the House gives NIH $415M raise, NCI gets $128M
Legislation caps proportion of NIH grants to receive multiyear funding; indirect costs remain untouched

The U.S. House of Representatives Jan. 22 passed a three-bill minibus package that is expected to be the grand finale of the drama of the fiscal year 2026 appropriations process. The package, which funds the HHS as well as the departments of Defense, Transportation, Housing and Urban Development, Labor, and Education, gives NIH and NCI modest raises over FY25, and nullifies several  aggressive cuts the White House had proposed for NIH.
By Jacquelyn Cobb
Guest Editorial

Blood Cancer United: A new name at the right moment

This past summer, the organization I lead, formerly known as The Leukemia & Lymphoma Society, announced our new name: Blood Cancer United. It reflects our ongoing commitment to the entire blood cancer community—patients, families, caregivers, researchers, healthcare professionals, and partners—and our work to advance progress for those impacted by all types of blood cancer. 
By E. Anders Kolb
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account